English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/134241
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

AuthorsMatarraz, Sergio; Paiva, Bruno; Díez-Campelo, María; López-Corral, L.; Mateos, Maria Victoria; Hernández, M. Teresa ; San Miguel, Jesús F. ; Orfao, Alberto
KeywordsDiagnosis
Lenalidomide
Bone marrow cells
Multiple myeloma
Phenotypic alterations
Issue Date2012
PublisherFerrata Storti Foundation
CitationHaematologica 97(10): 1608-1611 (2012)
AbstractIncreased risk of acute myeloid leukemia/myelodysplastic syndromes following treatment has been reported in multiple myeloma, but whether dysplastic features are already present at diagnosis remains to be investigated. Using multiparameter flow cytometry, we analyzed the distribution and phenotype of bone marrow hematopoietic cells from 47 multiple myeloma patients (15 symptomatic and 32 high-risk smoldering). From the 32 smoldering myeloma patients, 18 were studied at baseline and 22 after nine cycles of lenalidomide/dexamethasone treatment following the QUIREDEX trial (including 8 from baseline). Phenotypic alterations of bone marrow cells of 7 (47%) symptomatic and 6 (33%) smoldering myeloma patients were detected at baseline; there was no difference in the frequency and extent of phenotypic alterations between symptomatic versus smoldering cases. Likewise, no difference was seen between smoldering myeloma patients studied at baseline versus after lenalidomide/dexamethasone treatment. Our results suggest that phenotypic alterations of bone marrow hematopoietic cells are often present in newly diagnosed symptomatic and smoldering multiple myeloma patients. QUIREDEX trial (NCT00480363)
DescriptionThis is an open-access paper.-- et al.
Publisher version (URL)http://dx.doi.org/10.3324/haematol.2012.064121
URIhttp://hdl.handle.net/10261/134241
DOI10.3324/haematol.2012.064121
Identifiersdoi: 10.3324/haematol.2012.064121
issn: 0390-6078
e-issn: 1592-8721
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Myelodysplasia-associated.pdf238,11 kBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.